GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol2018;17:954–76.doi:10.1016/S1474-4422(18)30322-3http://www.ncbi.nlm.nih.gov/pubmed/30353868
2.
TakagiH, UmemotoT, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale. J Cardiol2016;67:493–503.doi:10.1016/j.jjcc.2015.09.016http://www.ncbi.nlm.nih.gov/pubmed/26527111
3.
TariqN, TepperSJ, KrieglerJS, . Patent foramen ovale and migraine: closing the Debate–A review. Headache2016;56:462–78.doi:10.1111/head.12779http://www.ncbi.nlm.nih.gov/pubmed/26952049
4.
GuoY, ShiY, ZhuD, . Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale. J Investig Med2020;68:1250–5.doi:10.1136/jim-2020-001342http://www.ncbi.nlm.nih.gov/pubmed/32848048
Abu-ArafehI, HersheyAD, DienerH-C, . Guidelines of the International headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia2019;39:803–16.doi:10.1177/0333102419842188http://www.ncbi.nlm.nih.gov/pubmed/30947525
7.
SaccoS, BraschinskyM, DucrosA, . European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain2020;21:76. doi:10.1186/s10194-020-01130-5http://www.ncbi.nlm.nih.gov/pubmed/32546227
